Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and Adebrelimab in First-line HER2-overexpressing Non-squamous NSCLC
NCT07896005Phase 3Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2026
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07896005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896005.